MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.6056 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,045
Open 0.6056
Bid (Size) 0.6019 (100)
Ask (Size) 0.6160 (200)
Prev. Close 0.6056
Today's Range 0.6056 - 0.6056
52wk Range 0.5900 - 19.20
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
GeoVax Announces a Warrant Inducement Transaction
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-88.3%
-88.3%
1 Month
-16.4%
-16.4%
3 Month
-71.2%
-71.2%
6 Month
-61.9%
-61.9%
1 Year
-96.7%
-96.7%

More News

Read More
News headline image
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
Via NewMediaWire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
GeoVax Labs (GOVX): High Growth Stock Beats Earnings, Advances Mpox Vaccine and Cancer Therapy ↗
Via Chartmill
News headline image
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak
Via NewMediaWire
News headline image
GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies
Via NewMediaWire
News headline image
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
Via NewMediaWire
News headline image
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak
Via NewMediaWire
Topics Death
News headline image
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase
Via NewMediaWire
News headline image
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study
Via NewMediaWire
News headline image
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio
Via NewMediaWire
News headline image
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
Via NewMediaWire
News headline image
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
Via NewMediaWire
News headline image
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Via NewMediaWire
Topics Economy
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Via TheNewswire.com
Topics Economy
News headline image
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Via NewMediaWire
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Via TheNewswire.com
News headline image
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Via NewMediaWire
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Via TheNewswire.com
News headline image
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Via NewMediaWire
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Via TheNewswire.com
News headline image
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Via NewMediaWire
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Via TheNewswire.com
News headline image
Is Co-Diagnostics National Security’s Next Diagnostic Pick? ↗
Via MarketBeat

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 0.6056
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 09/01/26 04:00 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 1.32M
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story